Optimization of 5′ Untranslated Region of Modified mRNA for Use in Cardiac or Hepatic Ischemic Injury
Open Access
- 1 June 2020
- journal article
- research article
- Published by Elsevier BV in Molecular Therapy - Methods & Clinical Development
- Vol. 17, 622-633
- https://doi.org/10.1016/j.omtm.2020.03.019
Abstract
No abstract availableFunding Information
- National Institutes of Health (R01 HL142768-01)
This publication has 68 references indexed in Scilit:
- Driving vascular endothelial cell fate of human multipotent Isl1+ heart progenitors with VEGF modified mRNACell Research, 2013
- Successful Use of mRNA‐Nucleofection for Overexpression of Interleukin‐10 in Murine Monocytes/Macrophages for Anti‐inflammatory Therapy in a Murine Model of Autoimmune MyocarditisJournal of the American Heart Association, 2012
- Identification of Cytoplasmic Capping Targets Reveals a Role for Cap Homeostasis in Translation and mRNA StabilityCell Reports, 2012
- Using translational enhancers to increase transgene expression in DrosophilaProceedings of the National Academy of Sciences of the United States of America, 2012
- Gene Therapy for Heart FailureCirculation Research, 2012
- Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNACell Stem Cell, 2010
- The mechanism of eukaryotic translation initiation and principles of its regulationNature Reviews Molecular Cell Biology, 2010
- Sequence signatures and mRNA concentration can explain two‐thirds of protein abundance variation in a human cell lineMolecular Systems Biology, 2010
- Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological TargetsCell, 2009
- Yeast transcripts cleaved by an internal ribozyme provide new insight into the role of the cap and poly(A) tail in translation and mRNA decayRNA, 2006